ClinicalTrials.gg
Active, not recruitingNCT04761770Updated Feb 17, 2026

Study of a Geriatric Assessment to Plan a Treatment Approach for Older People With Various Blood Disorders

A Phase 2 interventional study of Geriatric assessment (GA) pre-transplant and conditioning regimen in Myelodysplastic Syndrome, Myeloproliferative Neoplasms and Chronic Myelomonocytic Leukemia, sponsored by Memorial Sloan Kettering Cancer Center. Active, not recruiting at 7 sites in United States. Open to participants aged 60 Years and older. Per ClinicalTrials.gov, last updated 2026-02-17.

Sponsored by Memorial Sloan Kettering Cancer Center · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
33
Allocation
Not applicable
Ages
60 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 50 studies in Myelodysplastic Syndromes by Memorial Sloan Kettering Cancer Center — 1 open to participants now, 5 under way, none of them phase 3. Myelodysplastic Syndromes · Memorial Sloan Kettering Cancer Center.

Enrollment
19th of 37
33 · median 33
Started
2021
with 2 others
Phase 2
29 of 50
1 open now
Registered
46th of 50
by date

Among the 50 studies in Myelodysplastic Syndromes by Memorial Sloan Kettering Cancer Center, this one is the 19th largest by enrollment of the 37 interventional ones that give a count, is one of 3 that started in 2021, is one of 29 in phase 2, and was the 46th registered.

Myelodysplastic Syndromes

1,997 studies on the registry are indexed under Myelodysplastic Syndromes; 318 are open to participants now.

Browse Myelodysplastic Syndromes studies →

Open to participants now

1 of the 50 studies in Myelodysplastic Syndromes by Memorial Sloan Kettering Cancer Center is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Where they have run

Who these studies take

Of the 259 Myelodysplastic Syndromes studies recruiting now, 166 (64%) set no upper age limit and 67 (26%) stop at 75 or younger; 55 take children under 18; 17 take healthy volunteers.

This study: 60 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 50 studies in Myelodysplastic Syndromes by Memorial Sloan Kettering Cancer Center, or all of them as a file.
02

Study summary

This study will evaluate whether a geriatric assessment can lead to better treatment outcomes in older patients (age 60+) with a myeloid malignancy including acute myeloid leukemia, ,myelodysplastic syndromes, myeloproliferative neoplasms, or related blood disorders who are going to receive chemotherapy or another treatment to prepare the body for an allogeneic hematopoietic stem cell transplant (allo-HCT). The geriatric assessment includes looking at patients' cognitive function (thinking processes), physical function, mobility (ability to move the body), mood, nutrition, and current medications to help decide the type of treatment they'll receive.

Another purpose of this study is to see whether use of the geriatric assessment improves participants' quality of life. We will evaluate participants' quality of life through questionnaires.

Read the detailed description

This is a prospective, phase II study evaluating the efficacy of a risk-adapted, personalized allo-HCT strategy based on geriatric vulnerabilities identified by pre-transplant GA. The less vulnerable/fit older patients are recommended to receive MA conditioning and the more vulnerable older patients are recommended to receive RIC/NMA conditioning.

  1. HCT-CI/Age ≤4 AND no IADL impairment (less vulnerable/fit) -> MA regimen
  2. HCT-CI/Age >4 AND/OR any IADL impairment (more vulnerable) -> RIC/NMA regimen

    • Chemotherapies: busulfan, fludarabine, melphalan, cyclophosphamide, thiotepa, clofarabine
    • Radiation therapy: total body irradiation (TBI)
    • Other therapy: anti-thymocyte globulin (ATG)
03

Conditions studied

  • Myelodysplastic Syndrome
  • Myeloproliferative Neoplasms
  • Chronic Myelomonocytic Leukemia
  • Atypical Chronic Myeloid Leukemia
  • Myelodysplastic/Myeloproliferative Overlapping Syndrome

Keywords

  • blood disorders
  • Allogeneic Hematopoietic Cell Transplant
  • 20-522
04

Who can participate

Ages eligible
60 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • are 60 years or older
  • have a confirmed myeloid including acute myeloid leukemia, ,myelodysplastic syndrome, myeloproliferative neoplasms, or related blood disorders including chronic myelomonocytic leukemia, atypical chronic myeloid leukemia, and myelodysplastic/myeloproliferative overlapping syndrome
  • have \<10% blasts in bone marrow prior to transplant
  • have a matched related or unrelated donor, mismatched unrelated donor, or haploidentical donor
  • Meet institutional standard criteria for transplantation as determined by the primary transplant physician
  • Undergoes transplantation using the allocated conditioning regimen intensity defined by the protocol-specified criteria below:

    • HCT-CI/Age \<5 and IADL normal = myeloablative regimen
    • HCT-CI/Age ≥5 and/or IADL impairment = RIC/NMA regimen

Exclusion criteria

Exclusion Criteria:

  • Prior hematopoietic cell transplantation
  • Cord blood donors
  • Persons with active, disease defined by ≥10% blasts in bone marrow prior to transplant
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
33 participants (actual)

Study arms

  • Experimental
    Geriatric participants with various blood disorders

    1. Geriatric assessment (GA) pre-transplant 2. Risk-adapted allocation of conditioning intensity based on GA 3. GA-directed, longitudinal supportive care management

    Other: Geriatric assessment (GA) pre-transplant · Drug: conditioning regimen · Procedure: Allogeneic CD34+ selected stem cells

Interventions

  • OtherGeriatric assessment (GA) pre-transplant

    Assessment of comorbidities, polypharmacy, and functional, nutritional, and psychosocial impairment.

  • Drugconditioning regimen

    Based on the Geriatric assessment. 1. HCT-CI/Age ≤4 AND no IADL impairment (less vulnerable/fit) -\> Myeloablative (MA) regimen 2. HCT-CI/Age \>4 AND/OR any IADL impairment (more vulnerable) -\> Reduced-intensity (RIC)/Nonmyeloablative (NMA) regimen

  • ProcedureAllogeneic CD34+ selected stem cells

    Stem cells are collected as per institutional guidelines. CD34+ enriched stem cells will be obtained using the FDA approved reagents from Miltenyi, according to the instruction manual.

06

What researchers measure

Primary outcomes

  1. cumulative incidence of non-relapse mortality (NRM)

    defined as death in the absence of relapse/disease progression.

    Time frame: 1 year

07

Study locations

7 sites
08

References and documents

Individual participant data

Plan to share: Yes — Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made beginning 12 months after publication and for up to 36 months post publication. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2021 (actual). Primary completion is estimated for Feb 2027, 72 months after the start.

Of 227 non-industry phase 2 interventional studies under Myelodysplastic Syndromes, half reached primary completion within 75 months of starting (the median), counting those still running; a quarter within 44 and three quarters within 116. This study's planned 72 months is close to that.

Counting every sponsor, half of 279 studies reached it within 65 months; a quarter within 39 and three quarters within 104.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 16, 2021
First posted
Feb 21, 2021
StartActual
Feb 15, 2021
Primary completionEst.
Feb 2027
CompletionEst.
Feb 2027
Last update
Feb 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04761770
Responsible party
Sponsor
First posted
Feb 21, 2021
Start date
Feb 15, 2021
Primary completion
Feb 2027 (estimated)
Completion
Feb 2027 (estimated)
Last update
Feb 17, 2026

Study contacts

Richard J Lin, MD, PhD
principal investigator · Memorial Sloan Kettering Cancer Center

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion